As pharmacovigilance teams face increasing ICSR volumes, tighter reporting timelines, and ongoing resource constraints, Artificial Intelligence (AI) is becoming a strategic tool for improving operational efficiency. However, in a regulated environment, automation alone is not enough. Before AI can be deployed at scale, Quality Units must be confident that performance is measurable, reproducible, and supported by robust validation evidence.
The question is no longer whether AI can improve pharmacovigilance operations. The real question is whether AI can be validated, governed, and defended during audits and inspections. Organizations need objective evidence demonstrating that AI-enabled workflows remain compliant, transparent, and under human oversight throughout their lifecycle.
AB Cube’s SafetyEasy® AI Suite was designed specifically for regulated pharmacovigilance environments. By combining AI-powered automation with validation frameworks, reproducibility testing, confidence scoring, and audit-ready documentation, SafetyEasy® enables organizations to accelerate drug safety operations without compromising quality or compliance.
What Is Validated AI in Pharmacovigilance?
Validated AI in pharmacovigilance refers to AI-enabled systems that have been assessed against predefined performance, quality, reproducibility, and compliance criteria before being used in regulated workflows. Unlike general AI applications, validated AI must provide evidence that outputs are consistent, traceable, and suitable for GxP-regulated environments.
For pharmacovigilance teams, validation is essential because AI-generated outputs can influence critical processes such as case intake, coding, literature review, and medical information management. Quality Units must be able to demonstrate that AI systems perform as intended and remain under appropriate governance and oversight.
Validated AI combines automation with accountability, helping organizations improve efficiency while maintaining inspection readiness and patient safety standards.
How AI Is Transforming Pharmacovigilance Operations
The volume of Individual Case Safety Reports (ICSRs) continues to increase across the industry, placing growing pressure on pharmacovigilance teams. At the same time, organizations must maintain compliance, meet reporting timelines, and manage limited specialist resources.
AI in pharmacovigilance helps address these challenges by automating repetitive activities, reducing manual processing, and allowing highly trained professionals to focus on scientific and clinical decision-making. From case intake and coding to literature review and narrative writing, AI-powered pharmacovigilance automation can significantly improve operational efficiency while maintaining appropriate controls.
The challenge is not simply introducing AI into drug safety operations. It is ensuring that AI remains transparent, controlled, and compliant throughout its lifecycle.
AI-Powered Pharmacovigilance Automation Across Critical Workflows
SafetyEasy® AI Suite applies validated AI to the pharmacovigilance workflows that typically consume the greatest amount of operational effort.
Case Intake Automation
Automatically converts both unstructured and structured source data into coded, database-ready cases. Whether processing emails, narratives, PDFs, web forms, or EDC data, the module automates extraction, coding, and data entry with built-in confidence scoring. Organizations can reduce manual effort by up to 90%, accelerate intake from hours to minutes, and significantly improve data quality and consistency.
Follow-Up Narrative Generation
Generates draft follow-up narratives for human review and finalization, allowing pharmacovigilance professionals to dedicate more time to medical review, benefit-risk assessment, and signal detection.
AI-Assisted Literature Review
Identifies and flags adverse event-relevant content within scientific literature, helping teams focus on meaningful safety signals while reducing time spent reviewing non-relevant publications.
Medical Information Management
Supports medical information teams through AI-assisted transcription, summarization, and response generation, enabling faster and more consistent communications while maintaining quality and compliance.
Benefits of AI in Pharmacovigilance for Drug Safety Teams
The value of AI in pharmacovigilance extends far beyond productivity gains.
Every hour saved through automated case intake, coding, transcription, and document processing is an hour that can be redirected toward higher-value activities such as medical review, signal detection, risk management, and benefit-risk evaluation.
For drug safety teams, AI-powered pharmacovigilance automation delivers several important benefits:
- Reduced manual data entry and transcription effort
- Faster ICSR processing and case creation
- Improved consistency across safety workflows
- Enhanced scalability without proportional headcount growth
- Better resource allocation toward scientific review activities
- Stronger compliance through controlled and traceable processes
By automating repetitive tasks, organizations can focus their expertise where it matters most: protecting patient safety and supporting regulatory compliance.
How EvalAI Validates AI Performance Using Your Own Pharmacovigilance Data
For AI to be trusted in a regulated pharmacovigilance environment, performance must be measurable, reproducible, and explainable. Quality Units and inspectors require objective evidence that AI outputs are accurate, consistent, and operating within defined acceptance criteria.
EvalAI provides a structured framework for evaluating AI performance using an organization’s own representative data. This enables teams to assess AI capabilities within their specific operating environment and quality framework.
AI Accuracy
Measures fidelity, consistency, completeness, and interpretation against source data using weighted scoring criteria tailored to specific case sections.
Human Alignment
Compares AI outputs directly with human-generated results, helping organizations understand where AI matches, exceeds, or falls below expected performance levels.
Reproducibility
Evaluates the consistency of AI outputs by performing multiple runs against the same cases and applying structured comparison methodologies. Demonstrating predictable behaviour is essential in GxP-regulated environments.
Confidence Scoring
Assigns confidence levels to extracted information and generated outputs, automatically highlighting low-certainty results that require additional human review.
Inspection-Ready Evidence for Quality Units
EvalAI’s independent AI Judge performs blind assessments to reduce evaluation bias and provides detailed drill-down evidence at case-section level. Campaign reporting, reproducibility data, AI-versus-human comparisons, and traceable scoring help organizations demonstrate how AI performance was assessed and approved within their quality framework.
How to Validate AI for Pharmacovigilance and GxP Compliance
Validation remains one of the biggest barriers to AI adoption in regulated environments. While many organizations recognize the benefits of AI, they often struggle with the effort required to establish an appropriate validation framework.
AB Cube addresses this challenge through a structured, risk-based validation approach designed specifically for pharmacovigilance and GxP compliance. EvalAI generates the evidence, while the SDLC-WI-006 framework provides the governance structure around it.
Two-Layer Validation Framework
Combines GAMP5 principles with AI-specific assessments covering accuracy, relevance, reproducibility, and appropriateness.
Risk-Based Validation
Each AI-enabled function is classified according to its GxP impact, level of automation, degree of human oversight, data complexity, and error detectability.
Change Control and Revalidation
Model updates, prompt modifications, provider changes, and RAG configuration updates can trigger re-validation using the same methodology applied during initial deployment.
ISO 2859-1 Sampling and Continuous Monitoring
Validation activities are supported by statistically defensible sample sizes and ongoing monitoring practices to maintain confidence in AI performance over time.
Validation Documentation Included with Every AI Release
Every AI release is accompanied by a comprehensive documentation package designed to help Quality Units assess, validate, and govern AI-enabled functionality efficiently.
Documentation includes:
- Functional Specifications
- Validation Level Determination
- Validation Plan Templates
- Pre-Built Test Datasets
- EvalAI Campaign Results
- Monitoring Guidance
- Change Impact Assessments
Rather than starting from scratch, organizations receive a structured, inspection-ready foundation that significantly reduces validation effort while supporting compliance objectives.
Human Oversight and AI Governance in Pharmacovigilance
At AB Cube, AI is designed to support pharmacovigilance professionals, not replace them. Human expertise remains central to all critical safety decisions.
Confidence Scoring directs uncertain outputs to qualified reviewers, while comprehensive audit trails capture every input, output, and AI interaction. EvalAI’s AI Judge helps reduce evaluation bias, and responsibility for final review and approval always remains with trained pharmacovigilance personnel.
This approach ensures that AI-powered pharmacovigilance automation remains transparent, accountable, and aligned with regulatory expectations.
Why AB Cube Is Different from Other Pharmacovigilance AI Solutions
Many AI solutions focus primarily on automation. AB Cube focuses on automation and validation.
SafetyEasy® AI Suite combines operational efficiency with inspection-ready evidence, enabling organizations to accelerate pharmacovigilance workflows while maintaining confidence in the quality and reliability of AI-generated outputs.
With EvalAI, built-in confidence scoring, risk-based validation methodologies, comprehensive documentation packages, and strong human oversight controls, AB Cube provides a practical path to adopting AI in regulated drug safety environments.
Ready to See Validated AI for Pharmacovigilance in Action?
AB Cube helps pharmacovigilance teams automate case intake, coding, literature review, and medical information management while maintaining compliance, inspection readiness, and human oversight.
Book a personalized demonstration to:
- Evaluate AI performance on your own data
- Explore the EvalAI validation framework
- Review inspection-ready documentation
- Identify automation opportunities across your PV workflows
Schedule a demo today and discover how validated AI can transform your pharmacovigilance operations with confidence.
Book a demo
"*" indicates required fields
Frequently Asked Questions About AI in Pharmacovigilance
What is validated AI in pharmacovigilance?
Validated AI is AI that has been assessed against predefined performance, quality, reproducibility, and compliance criteria before being used in regulated pharmacovigilance workflows.
Can AI be used for ICSR processing?
Yes. AI can support case intake, coding, narrative drafting, literature review, and other pharmacovigilance activities while maintaining appropriate human oversight.
How do you validate AI for pharmacovigilance?
Validation requires performance testing, risk assessment, reproducibility analysis, change control processes, documentation, and ongoing monitoring. EvalAI provides evidence using representative organizational data.
Can AI be used in GxP-regulated environments?
Yes, provided that organizations establish appropriate validation, governance, monitoring, and human oversight mechanisms.
What are the benefits of AI in pharmacovigilance?
Key benefits include reduced manual effort, faster ICSR processing, improved consistency, greater scalability, and better resource utilization across drug safety operations.
How does EvalAI work?
EvalAI evaluates AI performance through AI Accuracy, Human Alignment, Reproducibility, and Confidence Scoring, generating objective evidence to support validation and inspection readiness.
